Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis

Inclusion Criteria

• •Age 18 or older
• •Patients who have biopsy evidence of autoimmune liver disease following liver transplantation and a different pre-transplant etiology of liver disease will be eligible.
• •Patients who have been treated with steroids or other immunosuppressive agents for at least a month and who have not responded either with respect to normalization of liver function tests or biopsy evidence of hepatitis will be eligible.
• •Ability to provide signed and dated IRB approved written consent in accordance with regulatory and institutional guidelines prior to any protocol-related procedure.
• •Women of child bearing potential agree to have pregnancy test at screening
• •Males agree use of appropriate contraceptives during the active Orenia dosing period
• •Age 18 or older
• •Patients who have biopsy evidence of autoimmune liver disease following liver transplantation and whose original etiology of liver disease was AIH will be eligible.
• •Patients who have been treated with steroids or other immunosuppressive agents for at least a month and who have not responded either with respect to normalization of liver function tests or biopsy evidence of hepatitis will be eligible.
• •Ability to provide signed and dated IRB approved written consent in accordance with regulatory and institutional guidelines prior to any protocol-related procedure.
• •Women of child bearing potential agree to have pregnancy test at screening
• •Males agree use of appropriate contraceptives during the active Orenia dosing period